Onychomycosis Treatment Market By Treatment Type (Topical, Oral, Laser, Combination); By Infection Type (Distal Subungual, White Superficial, Proximal Subungual, Candidal, Total Dystrophic); By Drug Type (Prescription, OTC, Natural Remedies); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Onychomycosis Treatment Market: Generic Volume, Premium Topicals, and Pharmacy Expansion Reshape Competition

The Global Onychomycosis Treatment Market was valued at USD 3.77 billion in 2025 and is projected to reach USD 6.38 billion by 2032, growing at a CAGR of 7.8%, according to Strategic Market Research.

 

The onychomycosis treatment market serves a large patient population, but only a limited share receives formal treatment. Revenue comes from oral antifungals, prescription topicals, medicated nail lacquers, over-the-counter products, and procedures such as nail debridement. Market performance depends on diagnosis, reimbursement, treatment initiation, and patient adherence throughout the prolonged treatment period.

 

U.S. Medicare beneficiaries filed more than 4.27 million 30-day prescriptions for onychomycosis treatments between 2016 and 2020, with spending reaching approximately USD 190.87 million. Medication costs rose by an average of 4% annually before declining in 2020, while most prescriptions remained concentrated in established low-cost therapies. (Medicare Part D onychomycosis prescribing analysis)

 

Low Treatment Conversion Restrains Prescription Demand

A large share of patients recognize fungal nail disease without entering formal treatment. A nationally representative U.S. survey found that 10% of adults reported a fungal nail infection during the preceding 12 months. A separate ambulatory-care analysis found that prescription treatment was provided at only 20% of onychomycosis visits. (U.S. fungal nail infection survey)

Mild cases are often treated as cosmetic concerns, while some patients delay care until nail thickening, pain, difficulty wearing footwear, or associated health conditions become more serious. Others purchase inexpensive non-prescription products without diagnostic testing. Long treatment periods, recurrence, uncertain cosmetic improvement, and out-of-pocket costs further reduce willingness to begin or complete therapy.

Diagnostic confirmation also affects access to prescription medicines. Nail psoriasis, trauma, and other nail disorders can resemble fungal infection, making visual examination alone unreliable. An analysis of the U.S. All of Us database found that Black and Hispanic patients were less likely than White patients to receive confirmatory testing. Lower testing rates can reduce appropriate treatment initiation and make it harder to satisfy payer requirements for higher-priced products. (All of Us onychomycosis study)

 

Low-Cost Medicines Control Prescription Volume

Ciclopirox and terbinafine accounted for nearly 99% of Medicare onychomycosis prescriptions between 2016 and 2020. Generic ciclopirox represented 99% of prescribing within its category, while generic itraconazole accounted for 91%. Physicians continue to favor familiar and inexpensive options when patient health and disease severity allow their use.

Oral terbinafine remains widely used because of its established clinical role, low generic cost, and effectiveness in suitable patients. Its use can be limited by drug interactions, liver-related concerns, multiple comorbidities, and patient reluctance to take systemic therapy. Older patients are more likely to present with these constraints, creating a role for topical products despite their longer treatment periods.

Ciclopirox serves as the main low-cost topical benchmark in the United States. Broad payer acceptance and low prescription cost support its volume, but suppliers compete mainly on formulary access, pharmacy availability, manufacturing cost, and prescriber familiarity. Limited differentiation leaves little room for premium pricing.

 

Premium Topicals Generate High Revenue per Patient

Efinaconazole and tavaborole occupy the high-value end of the U.S. topical segment. Medicare’s average prescription cost in 2021 was USD 1,035.38 for efinaconazole and USD 784.63 for tavaborole, compared with about USD 34.56 for ciclopirox. Efinaconazole generated approximately USD 20.4 million from 15,425 Medicare claims in 2023, allowing a relatively small beneficiary base to produce significant spending. (CDC Medicare topical antifungal analysis)

Affordability and insurance access strongly influence use. Patients earning more than USD 75,000 annually had 3.47 times the odds of receiving efinaconazole and 5.36 times the odds of receiving tavaborole in the All of Us study. Higher education was also associated with greater access to newer prescription therapies. Prior authorization, copayments, coverage exclusions, and diagnostic requirements shape the premium segment as much as physician preference.

Bausch Health’s Jublia demonstrates the revenue potential of a well-established branded topical. The product generated approximately USD 100 million in revenue in 2021, and Bausch has continued investing in consumer awareness and patient access. Ongoing promotional spending indicates that even an established brand must keep converting untreated patients and defending prescription demand. (Bausch Health 2021 Form 10-K)

Prescription growth does not translate fully into net revenue because rebates, discounts, patient-support costs, distribution fees, and payer negotiations reduce realized sales. Bausch has reported higher rebate provisions alongside increased Jublia gross sales, making formulary access and gross-to-net control important to brand profitability. (Bausch Health 2025 Form 10-Q)

 

Primary Care Provides Scale, While Specialists Concentrate Prescribing

Onychomycosis treatment is distributed across primary-care practices, dermatology clinics, podiatry offices, and pharmacies. A CDC analysis of the broader Medicare topical-antifungal category found that primary-care physicians wrote 40% of prescriptions in 2021. Nurse practitioners and physician assistants accounted for 21.4%, dermatologists for 17.6%, and podiatrists for 14.1%. Although the data include other fungal conditions, they demonstrate the importance of non-specialist clinicians in total prescription volume.

Dermatologists and podiatrists prescribed far more treatments per provider. Dermatologists averaged 87.1 topical-antifungal prescriptions per prescriber, while podiatrists averaged 67.2. The top 10% of prescribers accounted for 44.2% of all prescriptions. Pharmaceutical companies can reach a large share of treated demand through a relatively concentrated group of high-volume clinicians.

Pharmacies play a larger role in markets where treatments are sold without prescription. OTC availability reduces reliance on physician visits and reimbursement, while making pharmacist recommendation, shelf visibility, brand awareness, and out-of-pocket affordability more important.

 

Aging Expands Demand but Narrows Treatment Choice

Older adults account for a substantial share of diagnosed and reimbursed demand. Canadian research estimated an age- and sex-adjusted toenail onychomycosis prevalence of 6.4%, with the condition four times more common among people over 60 than among younger adults. Population aging is increasing the number of patients likely to seek care for thickened, painful, or functionally limiting nails. (Canadian onychomycosis prevalence study)

Older patients are also more likely to have diabetes, vascular disease, reduced mobility, and polypharmacy. These conditions increase the need for treatment while limiting suitable options. Oral products may require closer review because of drug interactions and monitoring, while topical treatment depends on sustained adherence. Podiatry-based debridement and combination care remain important for patients who cannot manage nail care independently.

Higher disease burden among older adults does not automatically favor premium topicals. Medicare data still show strong use of low-cost products, and many commercial copay-support programs exclude patients with federal healthcare coverage. Premium uptake depends on Part D coverage, prior-authorization rules, and the patient’s ability to meet remaining costs.

 

Japan Shows How Branded Topicals Raise Treatment Spending

Japan provides clear evidence that new topical medicines can increase market value without a comparable rise in disease prevalence. A nationwide claims analysis found that annual onychomycosis medication expenditure exceeded JPY 30 billion in fiscal years 2019 to 2021. Total costs more than doubled in fiscal 2015 compared with fiscal 2014 after the introduction and rapid uptake of efinaconazole. (Japan national onychomycosis claims study)

Efinaconazole became the dominant treatment in the Japanese claims analysis, particularly among older adults. The later introduction of oral fosravuconazole coincided with lower efinaconazole prescribing and a modest decline in total costs. Product route, reimbursement, guidelines, and physician preference can shift spending between competing therapies even when the treated population remains broadly stable.

Kaken Pharmaceutical’s Clenafin franchise also faces loss-of-exclusivity pressure. The company has warned that the Clenafin patent cliff will temporarily reduce profit after fiscal 2025. Generic entry is likely to redirect value away from the originator while preserving or expanding molecule-level prescription volume. (Kaken Pharmaceutical business plan update)

 

Europe Is Shifting Toward Pharmacy-Led Launches

Europe is becoming the main geographic expansion area for newer topical therapy. Moberg Pharma’s MOB-015 received national approvals in 13 European countries for mild-to-moderate fungal nail infections in adults. Seven countries allowed non-prescription sales, while six required prescriptions, creating different commercial requirements across national markets.

Prescription uptake depends on reimbursement, physician familiarity, and clinical support. OTC sales are shaped more by pharmacist recommendation, consumer promotion, brand recognition, and repeat use. Differences in product classification, pricing, and permitted claims require separate launch strategies across European markets.

Terclara was launched in Sweden in 2024 and Norway in 2025 through major pharmacy chains. Moberg later reported marketing approval in additional countries and continued preparations for wider rollout. Rather than building separate sales teams across Europe, the company partnered with Karo Healthcare.

Karo obtained marketing, distribution, and sales rights across 19 European markets covering approximately 500 million people. Karo funds commercial execution, while Moberg receives royalties and product-supply income. The arrangement lowers Moberg’s fixed selling costs and gives the product access to an established pharmacy network and antifungal portfolio. (Moberg Pharma 2025 year-end report)

 

Asia-Pacific Expansion Uses Existing Brands and Distribution

Moberg and Karo expanded their agreement in April 2026 to include Australia, New Zealand, South Korea, and Taiwan, representing a combined population of about 100 million. The partners plan to use the Lamisil brand, linking the nail-fungus product with an established athlete’s-foot franchise. Regulatory applications are still required in each market.

China was added in June 2026 through a cross-border e-commerce agreement. The initial approach offers earlier consumer access without waiting for the full general-trade approval pathway. Karo can use its existing Chinese e-commerce infrastructure while Moberg evaluates the additional data and regulatory work needed for a broader mainland launch.

South Korea offers a sizeable diagnosed base. National health-insurance research identified approximately 1.92 million patients and a prevalence rate of 3.49%. Reimbursement, local pricing, and regulatory requirements will determine how much of this population becomes accessible to newer premium products. (South Korean national prevalence study)

 

Generic Efinaconazole Increases U.S. Pricing Pressure

Generic competition is becoming more important in the premium topical segment. The FDA approved the first generic versions of efinaconazole in December 2020, although patents and launch timing delayed the immediate commercial effect. In February 2026, the FDA Orange Book added Alembic’s AB-rated efinaconazole topical solution, providing another approved alternative to Jublia. (FDA Orange Book February 2026 changes)

Additional generic suppliers can strengthen payer negotiating power, reduce net prices, and improve access for patients previously unable to obtain efinaconazole. Higher prescription volume may partly offset lower unit prices at the molecule level, but revenue is likely to move away from the originator toward generic manufacturers, pharmacies, and payers.

Jublia retains brand recognition, physician familiarity, and an established consumer presence. Those advantages will become harder to defend if equivalent products secure pharmacy stocking and preferred formulary placement at lower cost.

 

North America Leads in Commercial Scale and Data Transparency

North America provides the clearest public evidence on prescription volume, cost, provider behavior, and patient-access disparities. U.S. Medicare data capture both the size of recurring treatment demand and the divide between generic volume and branded value. Canada adds strong prevalence evidence and an established prescription market for oral and topical therapies.

North America benefits from higher branded-drug use, established pharmacy and reimbursement channels, direct consumer promotion, and detailed claims data. Growth is constrained by generic competition, prior authorization, patient copays, and continued use of lower-cost treatments.

 

Market Competition Is Moving Toward Access and Channel Execution

Generic terbinafine and ciclopirox will retain broad use because of cost, availability, and prescriber familiarity. Premium topical products will continue to generate higher revenue per patient but remain exposed to payer controls, generic substitution, and unequal access.

New entrants need more than clinical differentiation. Commercial adoption depends on pharmacy availability, affordable patient access, physician confidence, diagnostic confirmation, and treatment completion. Long regimens mean that an initial prescription does not guarantee adherence or repeat demand.

Suppliers with recognized antifungal brands, pharmacy relationships, payer experience, and consumer-education platforms hold an execution advantage. Karo is using the Lamisil brand and pharmacy network to support MOB-015, while Bausch continues to defend Jublia through awareness and access programs. Generic companies are entering premium molecules as exclusivity weakens.

The largest untapped group consists of patients who recognize a fungal nail problem but never begin or complete formal treatment. Better diagnostic access, realistic treatment expectations, lower patient costs, and closer engagement across primary care, podiatry, dermatology, and community pharmacy will determine how much of that population becomes recurring demand.

 

Onychomycosis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.77 Billion
Revenue Forecast in 2032	USD 6.38 Billion
Overall Growth Rate	CAGR of 7.8% (2024 – 2030)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Infection Type, By Drug Type, By Distribution Channel, By Geography
By Treatment Type	Topical, Oral, Laser, Combination
By Infection Type	Distal Subungual, White Superficial, Proximal Subungual, Candidal, Total Dystrophic
By Drug Type	Prescription, Over-the-Counter, Natural Remedies
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	- Rising diabetic and elderly populations - Innovation in topical delivery systems - Expanding OTC and e-pharmacy reach
Customization Option	Available upon request